ACM
NTLA icon

Aquatic Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Aquatic Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-95,196
Closed -$1.22M – 1585
2026
Q1 		$1.22M Buy
95,196
+21,347
+29% +$272K 0.04% 517
2025
Q4 		$664K Buy
+73,849
New +$1.02M 0.02% 662
2025
Q1 		– Sell
-182,434
Closed -$2.13M – 1523
2024
Q4 		$2.13M Buy
182,434
+90,634
+99% +$1.41M 0.06% 360
2024
Q3 		$1.89M Buy
91,800
+68,900
+301% +$1.59M 0.05% 374
2024
Q2 		$513K Buy
+22,900
New +$545K 0.02% 536
2024
Q1 		– Sell
-22,800
Closed -$695K – 1504
2023
Q4 		$695K Buy
22,800
+13,500
+145% +$388K 0.02% 550
2023
Q3 		$294K Buy
9,300
+5,600
+151% +$217K 0.01% 594
2023
Q2 		$151K Sell
3,700
-600
-14% -$24.3K 0.01% 743
2023
Q1 		$160K Sell
4,300
-15,800
-79% -$620K 0.01% 640
2022
Q4 		$701K Buy
+20,100
New +$956K 0.05% 413

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Aquatic Capital Management's NTLA Position: Q2 2026 in Review

Aquatic Capital Management sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 95,196 shares — an estimated $1.22M sold.

Aquatic Capital Management first reported a position in NTLA in Q4 2022 and held it in 10 quarters. The position peaked at $2.13M in Q4 2024. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Aquatic Capital Management reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Aquatic Capital Management sold 95,196 Intellia Therapeutics shares in Q2 2026, an estimated $1.22M.
  • Aquatic Capital Management first reported a position in Intellia Therapeutics in Q4 2022 and held it in 10 quarters.
  • Aquatic Capital Management's Intellia Therapeutics position peaked at $2.13M in Q4 2024.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.